Chronic Inflammatory Activation in Fat Tissue: An Atherogenic Factor in Severe Coronary Artery Disease

University of Leipzig1 site in 1 country29 target enrollmentJuly 2007

ConditionsSevere Coronary Artery Disease Obesity Impaired Glucose Tolerance

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Severe Coronary Artery Disease
Sponsor: University of Leipzig
Enrollment: 29
Locations: 1
Primary Endpoint: change in endothelial function in severe coronary artery disease
Status: Terminated
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Chronic inflammatory activation in fat tissue can be the link between adiposity and an increased risk for atherosclerosis. The aim of this study is to investigate how molecular alterations in fat tissue can be influenced by regular physical exercise training alone or in combination with a medical therapy (glitazone or metformin) in obese patients with severe coronary artery disease (CAD) and impaired glucose tolerance.

Registry

clinicaltrials.gov

Start Date

July 2007

End Date

July 2012

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Male

Investigators

Sponsor

University of Leipzig

Responsible Party

Principal Investigator

Axel Linke

Co-Investigator

University of Leipzig

Eligibility Criteria

Inclusion Criteria

•Either impaired glucose tolerance (2 hour plasma glucose concentration \> 7.8 and \< 11.1 mmol/L during an oral glucose tolerance test) or impaired fasting plasma glucose concentration ( \> 6.0 and \< 7.0 mmol/L)
•Body mass index (BMI) \> 25
•Severe coronary artery disease determined by coronary angiography
•Male patients aged 35-75 years

Exclusion Criteria

•Diabetes mellitus type I
•Diabetes mellitus type II in combination with glycosylates hemoglobin \> 6.0%, previous medication with oral antidiabetic agents or insulin, fasting plasma glucose concentration \> 11.0 mmol/L
•Unstable angina pectoris
•Myocardial infarction within the last 4 weeks
•Reduced left-ventricular systolic function \< 30%